Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Core Insights - Amgen reported early Phase 2 data indicating that patients were able to maintain weight loss with less frequent dosing, which could serve as a competitive advantage over Eli Lilly and Novo Nordisk [1] Company Summary - Amgen's Phase 2 data suggests a potential differentiation in its weight management treatment by allowing less frequent dosing while still achieving weight maintenance [1]